ITOSiTeos Therapeutics, Inc.

Nasdaq iteostherapeutics.com


$ 17.05 $ -0.60 (-3.39 %)    

Tuesday, 28-May-2024 15:59:55 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 17.08
$ 17.38
$ 17.03 x 344
$ 0.00 x 0
$ 16.85 - $ 17.45
$ 8.20 - $ 18.75
525,151
na
612.2M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-06-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-24-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 09-01-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-iteos-therapeutics-raises-price-target-to-46

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ITeos Therapeutics (NASDAQ:ITOS) with a Buy and raises the ...

Core News & Articles
Market-Moving News for May 10th
05/10/2024 12:41:27

ITOS: 39% | iTeos Therapeutics shares are trading higher after the company announced a $120 million registered direct offering ...

 iteos-therapeutics-q1-2024-gaap-eps-107-misses-102-estimate

ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of ...

 jp-morgan-maintains-overweight-on-iteos-therapeutics-lowers-price-target-to-27

JP Morgan analyst Brian Cheng maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from ...

 hc-wainwright--co-reiterates-buy-on-iteos-therapeutics-maintains-44-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:ITOS) with a Buy and maintains ...

 iteos-therapeutics-q4-eps-085-beats-103-estimate-cash-and-investment-position-of-6327m-is-expected-to-provide-cash-runway-through-2026

ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(...

 iteos-to-highlight-preclinical-data-on-first-in-class-eos-984-targeting-ent1-at-the-american-association-for-cancer-research-annual-meeting-2024

iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

 iteos-announces-2024-strategic-priorities-and-anticipated-milestones-cash-balance-and-investment-balance-of-6449m-as-of-september-30-2023-expected-to-provide-runway-through-2026

- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab ...

 jp-morgan-maintains-overweight-on-iteos-therapeutics-lowers-price-target-to-29

JP Morgan analyst Daniel Wolle maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from...

 iteos-therapeutics-q3-eps-090-beats-120-estimate-cash-cash-equivalents-and-investments-position-was-6449m-expected-to-provide-runway-through-2026

ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...

 wedbush-reiterates-outperform-on-iteos-therapeutics-maintains-33-price-target

Wedbush analyst David Nierengarten reiterates ITeos Therapeutics (NASDAQ:ITOS) with a Outperform and maintains $33 price tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION